About | Slow Ledger 10

Our editorial approach

Slow Ledger 10 exists to separate early experimental findings from established clinical care and to help readers weigh uncertainty and risk. Our mission: Lattice Fern is an independent resource on ibogaine, GDNF, Parkinson’s disease, and the evidence behind experimental neurorestorative claims. We aim to be plainspoken, evidence-first, and careful about limits of knowledge.

How we source and vet information

We compile material from primary literature, clinical registries, systematic reviews, and official guidance, and we emphasize transparency about evidence quality. For example, when we summarize trial outcomes we consult trial registries and peer-reviewed reports rather than relying on press summaries, and we cross-check clinical terminology with established references such as the National Library of Medicine's PubMed entries and registry listings at ClinicalTrials.gov (ClinicalTrials.gov).

What we cover

Our coverage includes summaries of experimental research, explanation of methodological strengths and weaknesses, safety and regulatory context, and plain-language summaries meant for people affected by the conditions discussed. We organize writing into primer pieces, timeline narratives, and focused safety briefings so readers can choose the depth and format that fits their needs. Our site also links to accessible educational resources such as the Parkinson's disease overview on Wikipedia for foundational context.

Who this is for

This resource is written for people affected by Parkinson’s, care partners, and others seeking careful context about experimental research. If you arrived here seeking the broader site collection, our main hub offers topic-focused materials and indexes; for an entry point to the site's topical materials see the home index with summaries and navigation to primer pages at the site root (we link back to the central collection in situ on pages such as the site index and topical landing).

Editorial principles

E
Evidence before hype
We privilege peer-reviewed data and registries over claims made in promotional contexts.
S
Safety context
We foreground known risks and practical safety considerations when describing experimental work.
C
Plain language
Complex methods and statistics are explained in straightforward terms for non-expert readers.
H
Scientific humility
We note uncertainty and avoid overstating preliminary results.
I
Independence
We avoid financial or clinical affiliations that could bias reporting.

How we organize content

Content is grouped by format: primers explain methods and terms; timelines trace research developments; safety briefings synthesize risk-focused findings. For editorial or services inquiries we maintain a clear separation between reporting and any advisory or editorial services offered via our site’s pages; see our Services page for scope and offerings (services overview).

Sourcing standards

We prioritize primary sources and official registries. Where appropriate we reference regulatory guidance and established institutional repositories such as academic publisher hubs and university pages to corroborate claims; this practice mirrors standards described by public research libraries like the U.S. National Library of Medicine (nlm.nih.gov).

Contact the editors

Independent by design

Slow Ledger 10 is intentionally structured as an independent information resource. We are not a clinic, medical provider, or licensed treatment center; our content is not medical or legal advice. This disclosure is central to our work and appears on every page to avoid confusion about the site's role.

When readers want context about services or practical options, we describe where to look and which registries and institutional sources may be helpful — for example, trial registries and university or government summaries — rather than offering clinical recommendations. We also link to community-facing resources when they contextualize risk or access pathways; one site that tracks certain clinical activities in the field is Ibogaine Gabon, which we reference only as an example of a regional program description and never as an endorsement.

A note on evidence and uncertainty

Scientific claims evolve. We encourage readers to consult primary trial reports and official registries when making decisions and to discuss medical options with licensed clinicians. For accessible descriptions of research methods and evidence grading, many readers find overviews from university resources helpful; an example resource on evidence assessment practices is available via educational institutions that document systematic review standards (Cochrane).

Who we serve and how to use this site

Our audience includes people affected by Parkinson’s, their care partners, clinicians seeking succinct context, and interested readers. Use primers for background, timelines for progress tracking, and safety briefings to understand known harms and limitations. If you arrive from an external referral, our Services page outlines editorial engagements and how we support accessible summaries (learn about services).

Closing

Slow Ledger 10 takes a cautious stance toward emerging claims and centers safety and clarity. We welcome informed readers and emphasize transparency about sources and uncertainty. For a navigational entry point to the site's main materials, the site's root index consolidates primers, timelines, and safety briefings — return to the primary collection when you want to move between formats (site index and collection).

"Evidence before hype. Safety context. Plain language. Scientific humility. Independence." — Our editorial touchstones.